EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy

Toshiki Anami, Cheng Pan, Yukio Fujiwara iD, Yoshihiro Komohara iD, Hiromu Yano iD, Yoichi Saito iD, Masamichi Sugimoto, Daiko Wakita iD, Takanobu Motoshima, Yoji Murakami, Junji Yatsuda, Naofumi Takahashi und 4 weitere

Cancer Science · 2024

DOI: 10.1111/cas.16003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Toshiki Anami und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sinus macrophages in draining lymph nodes (DLNs) are involved in anti‐tumor immune reactions. CD169 (Sialoadhesin, Siglec‐1) is expressed on sinus macrophages and is considered a surrogate marker for the immunostimulatory phenotype of macrophages. In this study, the significance of sinus macrophages in immunotherapy was evaluated using mouse models. Treatment with anti‐programmed death‐ligand 1 (PD‐L1) antibody suppressed the subcutaneous tumor growth of MC38 and E0771 cells but was not effective against MB49 and LLC tumors. Decreased cytotoxic T‐lymphocyte (CTL) infiltration in tumor tissues and CD169 expression in sinus macrophages were observed in MB49 and LLC cells compared to corresponding parameters in MC38 and E0771 cells. The anti‐tumor effects of the anti‐PD‐L1 antibody on MC38 and E0771 cells were abolished when sinus macrophages in DLNs were depleted, suggesting that sinus macrophages are involved in the therapeutic effect of the anti‐PD‐L1 antibody. Naringin activated sinus macrophages. Naringin inhibited tumor growth in MB49‐ and LLC‐bearing mice but did not affect that in MC38‐ and E0771‐bearing mice. The infiltration of CTLs in tumor tissues and their activation were increased by naringin, and this effect was impaired when sinus macrophages were depleted. Combination therapy with naringin and anti‐PD‐L1 antibody suppressed MB49 tumor growth. In conclusion, CD169‐positive sinus macrophages in DLNs are critical for anti‐tumor immune responses, and naringin suppresses tumor growth by activating CD169‐positive sinus macrophages and anti‐tumor CTL responses. The activation status of sinus macrophages has been suggested to differ among tumor models, and this should be investigated in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsAnimalsMiceT-Lymphocytes, CytotoxicAntibodiesImmunotherapyMacrophagesB7-H1 AntigenCell Line, Tumor

Stichwörter der Autor:innen

CD169lymph nodemacrophagesnaringintumor immunity

Substanzen

Antineoplastic AgentsAntibodiesB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, Japan.
  • Laboratory of Bioengineering, Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto, Japan.
  • Product Research Department, Chugai Pharmaceutical, Kamakura, Japan.
  • Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Yukio Fujiwara, Yoshihiro Komohara, Hiromu Yano, Yoichi Saito, Daiko Wakita, Koji Tamada

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Anami, T., Pan, C., Fujiwara, Y., Komohara, Y., Yano, H., Saito, Y., Sugimoto, M., Wakita, D., Motoshima, T., Murakami, Y., Yatsuda, J., Takahashi, N., Suzu, S., Asano, K., Tamada, K., & Kamba, T. (2024). Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy. Cancer Science. https://doi.org/10.1111/cas.16003

Vancouver

Anami T, Pan C, Fujiwara Y, Komohara Y, Yano H, Saito Y, et al. Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy. Cancer Science. 2024. doi:10.1111/cas.16003

BibTeX
@article{Anami2024,
  author = {Anami, Toshiki and Pan, Cheng and Fujiwara, Yukio and Komohara, Yoshihiro and Yano, Hiromu and Saito, Yoichi and Sugimoto, Masamichi and Wakita, Daiko and Motoshima, Takanobu and Murakami, Yoji and Yatsuda, Junji and Takahashi, Naofumi and Suzu, Shinya and Asano, Kenichi and Tamada, Koji and Kamba, Tomomi},
  title = {Dysfunction of sinus macrophages in tumor‐bearing host induces resistance to immunotherapy},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16003}
}
Kostenlos starten →